The Goldman Sachs Group Has Lowered Expectations for Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price

Olema Pharmaceuticals (NASDAQ:OLMA) had its price objective decreased by analysts at The Goldman Sachs Group from $38.00 to $27.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. The Goldman Sachs Group’s price target would indicate a potential upside of 80.48% from the stock’s current price.

A number of other research firms also recently issued reports on OLMA. Guggenheim decreased their price objective on Olema Pharmaceuticals from $40.00 to $38.00 and set a “buy” rating for the company in a report on Tuesday. HC Wainwright dropped their target price on shares of Olema Pharmaceuticals from $45.00 to $38.00 and set a “buy” rating on the stock in a report on Monday, March 9th. JPMorgan Chase & Co. upped their target price on shares of Olema Pharmaceuticals from $29.00 to $32.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 18th. TD Cowen reiterated a “buy” rating on shares of Olema Pharmaceuticals in a research note on Monday, March 9th. Finally, UBS Group began coverage on shares of Olema Pharmaceuticals in a research report on Wednesday, January 7th. They set a “buy” rating and a $45.00 price target for the company. Eleven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $44.40.

Olema Pharmaceuticals Stock Up 2.7%

Shares of NASDAQ:OLMA opened at $14.96 on Wednesday. Olema Pharmaceuticals has a 52-week low of $2.86 and a 52-week high of $36.26. The firm has a market capitalization of $1.03 billion, a P/E ratio of -8.04 and a beta of 1.92. The stock has a 50 day moving average price of $23.35 and a 200-day moving average price of $18.67. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.03 and a current ratio of 9.95.

Olema Pharmaceuticals (NASDAQ:OLMA) last released its earnings results on Monday, March 16th. The company reported ($0.50) EPS for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.01. As a group, equities research analysts anticipate that Olema Pharmaceuticals will post -2.33 EPS for the current fiscal year.

Insider Buying and Selling at Olema Pharmaceuticals

In other news, insider David C. Myles sold 50,000 shares of the stock in a transaction on Tuesday, January 13th. The stock was sold at an average price of $27.60, for a total value of $1,380,000.00. Following the sale, the insider directly owned 542,761 shares of the company’s stock, valued at approximately $14,980,203.60. This represents a 8.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Shawnte Mitchell sold 25,000 shares of the firm’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $24.25, for a total value of $606,250.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 419,701 shares of company stock valued at $11,603,868 in the last ninety days. Corporate insiders own 16.36% of the company’s stock.

Hedge Funds Weigh In On Olema Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Titleist Asset Management LLC purchased a new stake in shares of Olema Pharmaceuticals during the second quarter valued at approximately $64,000. Diadema Partners LP increased its position in shares of Olema Pharmaceuticals by 153.7% during the second quarter. Diadema Partners LP now owns 253,657 shares of the company’s stock valued at $1,081,000 after acquiring an additional 153,657 shares in the last quarter. Candriam S.C.A. raised its holdings in Olema Pharmaceuticals by 46.9% in the 3rd quarter. Candriam S.C.A. now owns 1,249,727 shares of the company’s stock worth $12,235,000 after acquiring an additional 399,273 shares during the last quarter. Birchview Capital LP purchased a new position in Olema Pharmaceuticals in the 2nd quarter worth approximately $571,000. Finally, Kingdon Capital Management L.L.C. bought a new position in Olema Pharmaceuticals in the 3rd quarter valued at approximately $8,361,000. Institutional investors own 91.78% of the company’s stock.

Olema Pharmaceuticals News Summary

Here are the key news stories impacting Olema Pharmaceuticals this week:

• Positive Sentiment: Jefferies initiated coverage with a “Buy” and $40 price target (large upside vs. current levels), giving fresh institutional endorsement that can attract buyers. Jefferies Initiates Coverage – Benzinga
• Positive Sentiment: JPMorgan raised its price target to $58 and kept an “Overweight” stance — a high-profile upward revision that can drive momentum and re-rate expectations. JPMorgan Raises Price Target – Benzinga
• Positive Sentiment: HC Wainwright lifted EPS estimates across 2026–2030 and reiterated a “Buy” with a $38 target, signaling analyst confidence in improving fundamentals over the medium term. HC Wainwright Estimate Raises – MarketBeat
• Positive Sentiment: Olema reported better‑than‑expected quarterly results this week, which, along with raised analyst outlooks, is a near‑term bullish catalyst supporting the stock. Earnings Beat Drives Stock – AmericanBankingNews
• Positive Sentiment: Upcoming/preclinical data (palazestrant and OP‑3136) to be presented at AACR and a large reported $68.7M investor bet on a 2027 breast‑cancer launch are potential medium‑term catalysts for upside if data or investor interest validates the story. AACR Presentation – BusinessInsider Large Bet Report – The Globe and Mail
• Neutral Sentiment: Zacks notes the stock has been heavily sold (down ~33% over 4 weeks) and is technically oversold; that increases the chance of a short‑term bounce but also underscores elevated downside risk if catalysts disappoint. Oversold / Technical Note – Zacks
• Negative Sentiment: Guggenheim published a pessimistic forecast and an analyst downgrade hit headlines, pressuring the stock intraday — a reminder that not all desks are aligned with the recent bullish notes. Guggenheim Pessimistic Forecast – AmericanBankingNews
• Negative Sentiment: AmericanBankingNews reported an analyst downgrade that coincided with a notable intra‑day pullback, illustrating how mixed analyst views are fueling volatility. Analyst Downgrade / Price Reaction – AmericanBankingNews
• Negative Sentiment: Goldman Sachs trimmed its price target from $38 to $27 (while keeping a “Buy”), which reduces the consensus upside and may cap near‑term rallies until data or execution de‑risk the story. Goldman Lowers Target – Benzinga

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.